Alpelisib Efficacy without Cherry-PI3King Mutations.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36626159.
- Also identified by DOI 10.1158/1078-0432.CCR-22-3411 and PMC identifier 10023365.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The PI3K inhibitor alpelisib is clinically approved for the treatment of metastatic estrogen receptor-positive breast cancers harboring hotspot mutations in PIK3CA, which encodes a subunit of PI3K. Prospective clinical trial results demonstrated benefit from alpelisib for the treatment of advanced ER+ breast cancers harboring PIK3CA mutations in the hotspots of exons 7, 9, and 20. However, 20% of PIK3CA mutations occur in non-hotspot regions. A recent article demonstrated that patients with cancers bearing non-hotspot PIK3CA mutations also derived benefit from alpelisib, which will inform clinical decision-making moving forward. See related article by Rugo et al., p. 1056.
Medical subject headings
- Phosphatidylinositol 3-Kinases
- Breast Neoplasms